Oppenheimer Cuts OnKure Therapeutics (NASDAQ:OKUR) Price Target to $30.00

OnKure Therapeutics (NASDAQ:OKUR) had its price target cut by Oppenheimer from $35.00 to $30.00 in a research note released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also recently commented on the company. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Leerink Partners initiated coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective for the company. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $34.33.

OnKure Therapeutics Stock Performance

OKUR stock opened at $4.62 on Tuesday. OnKure Therapeutics has a twelve month low of $4.55 and a twelve month high of $20.00. The company has a 50 day moving average of $5.82. The company has a market capitalization of $15.44 million, a P/E ratio of -0.38 and a beta of 0.28.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, equities analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Trading of OnKure Therapeutics

Several large investors have recently modified their holdings of OKUR. Vestal Point Capital LP acquired a new stake in OnKure Therapeutics in the fourth quarter worth $5,461,000. Two Sigma Advisers LP acquired a new stake in shares of OnKure Therapeutics in the 4th quarter valued at about $122,000. Tang Capital Management LLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at about $2,534,000. Shay Capital LLC acquired a new position in OnKure Therapeutics during the 4th quarter worth approximately $129,000. Finally, Sphera Funds Management LTD. bought a new position in OnKure Therapeutics in the fourth quarter worth approximately $751,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.